Inventor · disambiguated record
Vanessa Soros
Also filed as: SOROS VANESSA · SOROS VANESSA B
11 granted patents·8 pending applications·0 citations·filing 2007–2025
81Inventor score
Files withVERTEX PHARMA6TRISHULA THERAPEUTICS INC5CATALYST BIOSCIENCES INC3TIZONA THERAPEUTICS3DAVID GLADSTONE INST1
Top patents by PatentIndex Score
19 records- 0185US12173337B2Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useVERTEX PHARMA·Filed 2023·Granted Dec 24, 2024·0 cites·48 claims
- 0278US11807882B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useVERTEX PHARMA·Filed 2021·Granted Nov 7, 2023·0 cites·56 claims
- 0377US2025026850A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0474US12331334B2Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·65 claims
- 0573US10954501B2Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Mar 23, 2021·0 cites·44 claims
- 0672US11401513B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2020·Granted Aug 2, 2022·0 cites·41 claims
- 0769US10781435B2Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of useCATALYST BIOSCIENCES INC·Filed 2018·Granted Sep 22, 2020·0 cites·38 claims
- 0866US2022372163A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0966US2025263683A1Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2025·Application pending·0 cites
- 1066US2022340680A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1165US2021403593A1Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1265US2024117334A1Factor b proteasesVERTEX PHARMA·Filed 2023·Application pending·0 cites
- 1362US12264199B2Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodiesTIZONA THERAPEUTICS·Filed 2021·Granted Apr 1, 2025·0 cites·7 claims
- 1462US2025367239A1Compositions and methods for non-genotoxic conditioningMARO BIO INC·Filed 2023·Application pending·0 cites
- 1559US2025353913A1Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodiesTIZONA THERAPEUTICS·Filed 2025·Application pending·0 cites
- 1658US11345757B2Anti-CD39 antibodiesTRISHULA THERAPEUTICS INC·Filed 2018·Granted May 31, 2022·0 cites·7 claims
- 1758US11208487B2Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodiesTIZONA THERAPEUTICS·Filed 2019·Granted Dec 28, 2021·0 cites·10 claims
- 1852US11613744B2Modified urokinase-type plasminogen activator polypeptides and methods of useVERTEX PHARMA·Filed 2020·Granted Mar 28, 2023·0 cites·77 claims
- 1946US7723021B2Methods for treating lentivirus infectionsDAVID GLADSTONE INST·Filed 2007·Granted May 25, 2010·0 cites·65 claims
Join the waitlist — get patent alerts
Get an alert when Vanessa Soros files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →